vs

Side-by-side financial comparison of Comstock Holding Companies, Inc. (CHCI) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is the larger business by last-quarter revenue ($44.6M vs $23.9M, roughly 1.9× Comstock Holding Companies, Inc.). Comstock Holding Companies, Inc. runs the higher net margin — 56.3% vs -90.4%, a 146.7% gap on every dollar of revenue. On growth, Comstock Holding Companies, Inc. posted the faster year-over-year revenue change (41.5% vs 13.8%). Over the past eight quarters, Comstock Holding Companies, Inc.'s revenue compounded faster (50.0% CAGR vs 7.3%).

The Comstock Lode is a lode of silver ore located under the eastern slope of Mount Davidson, a peak in the Virginia Range in Virginia City, Nevada, which was the first major discovery of silver ore in the United States and named after Canadian miner Henry Comstock.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

CHCI vs PACB — Head-to-Head

Bigger by revenue
PACB
PACB
1.9× larger
PACB
$44.6M
$23.9M
CHCI
Growing faster (revenue YoY)
CHCI
CHCI
+27.7% gap
CHCI
41.5%
13.8%
PACB
Higher net margin
CHCI
CHCI
146.7% more per $
CHCI
56.3%
-90.4%
PACB
Faster 2-yr revenue CAGR
CHCI
CHCI
Annualised
CHCI
50.0%
7.3%
PACB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CHCI
CHCI
PACB
PACB
Revenue
$23.9M
$44.6M
Net Profit
$13.5M
$-40.4M
Gross Margin
35.5%
37.1%
Operating Margin
32.4%
-92.3%
Net Margin
56.3%
-90.4%
Revenue YoY
41.5%
13.8%
Net Profit YoY
30.5%
-1802.7%
EPS (diluted)
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHCI
CHCI
PACB
PACB
Q4 25
$23.9M
$44.6M
Q3 25
$13.3M
$38.4M
Q2 25
$13.0M
$39.8M
Q1 25
$12.6M
$37.2M
Q4 24
$16.9M
$39.2M
Q3 24
$13.0M
$40.0M
Q2 24
$10.8M
$36.0M
Q1 24
$10.6M
$38.8M
Net Profit
CHCI
CHCI
PACB
PACB
Q4 25
$13.5M
$-40.4M
Q3 25
$541.0K
$-38.0M
Q2 25
$1.4M
$-41.9M
Q1 25
$1.6M
$-426.1M
Q4 24
$10.3M
$2.4M
Q3 24
$2.4M
$-60.7M
Q2 24
$946.0K
$-173.3M
Q1 24
$910.0K
$-78.2M
Gross Margin
CHCI
CHCI
PACB
PACB
Q4 25
35.5%
37.1%
Q3 25
11.0%
41.4%
Q2 25
19.0%
36.9%
Q1 25
18.6%
-3.7%
Q4 24
33.4%
25.6%
Q3 24
26.3%
25.0%
Q2 24
17.2%
16.5%
Q1 24
16.5%
29.1%
Operating Margin
CHCI
CHCI
PACB
PACB
Q4 25
32.4%
-92.3%
Q3 25
5.0%
-101.1%
Q2 25
13.7%
-112.8%
Q1 25
13.7%
-1154.5%
Q4 24
30.1%
-390.1%
Q3 24
21.8%
-160.3%
Q2 24
11.4%
-488.3%
Q1 24
10.8%
-209.6%
Net Margin
CHCI
CHCI
PACB
PACB
Q4 25
56.3%
-90.4%
Q3 25
4.1%
-98.9%
Q2 25
11.1%
-105.4%
Q1 25
12.6%
-1146.8%
Q4 24
61.1%
6.0%
Q3 24
18.3%
-151.9%
Q2 24
8.8%
-481.3%
Q1 24
8.6%
-201.4%
EPS (diluted)
CHCI
CHCI
PACB
PACB
Q4 25
$-0.11
Q3 25
$-0.13
Q2 25
$-0.14
Q1 25
$-1.44
Q4 24
$-0.44
Q3 24
$-0.22
Q2 24
$-0.64
Q1 24
$0.09
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHCI
CHCI
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$31.3M
$279.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$70.0M
$5.3M
Total Assets
$85.0M
$784.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHCI
CHCI
PACB
PACB
Q4 25
$31.3M
$279.5M
Q3 25
$26.2M
$298.7M
Q2 25
$30.5M
$314.7M
Q1 25
$28.3M
$343.1M
Q4 24
$28.8M
$389.9M
Q3 24
$21.1M
$471.1M
Q2 24
$17.4M
$509.8M
Q1 24
$16.2M
$561.9M
Stockholders' Equity
CHCI
CHCI
PACB
PACB
Q4 25
$70.0M
$5.3M
Q3 25
$56.3M
$36.1M
Q2 25
$55.5M
$61.5M
Q1 25
$53.7M
$91.6M
Q4 24
$52.4M
$506.6M
Q3 24
$41.7M
$453.1M
Q2 24
$39.2M
$492.7M
Q1 24
$37.9M
$649.0M
Total Assets
CHCI
CHCI
PACB
PACB
Q4 25
$85.0M
$784.1M
Q3 25
$67.6M
$803.2M
Q2 25
$65.2M
$825.5M
Q1 25
$62.8M
$860.8M
Q4 24
$64.9M
$1.3B
Q3 24
$52.2M
$1.5B
Q2 24
$48.6M
$1.5B
Q1 24
$46.8M
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHCI
CHCI
PACB
PACB
Operating Cash FlowLast quarter
$4.8M
$-19.1M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-44.6%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
0.36×
TTM Free Cash FlowTrailing 4 quarters
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHCI
CHCI
PACB
PACB
Q4 25
$4.8M
$-19.1M
Q3 25
$-3.2M
$-18.7M
Q2 25
$2.2M
$-29.4M
Q1 25
$582.0K
$-44.1M
Q4 24
$10.7M
$-30.6M
Q3 24
$3.9M
$-45.5M
Q2 24
$1.3M
$-54.3M
Q1 24
$-2.2M
$-75.7M
Free Cash Flow
CHCI
CHCI
PACB
PACB
Q4 25
$-19.9M
Q3 25
$-18.8M
Q2 25
$-29.9M
Q1 25
$-45.4M
Q4 24
$-32.3M
Q3 24
$-46.3M
Q2 24
$-55.7M
Q1 24
$-79.6M
FCF Margin
CHCI
CHCI
PACB
PACB
Q4 25
-44.6%
Q3 25
-48.9%
Q2 25
-75.3%
Q1 25
-122.3%
Q4 24
-82.3%
Q3 24
-115.7%
Q2 24
-154.8%
Q1 24
-205.0%
Capex Intensity
CHCI
CHCI
PACB
PACB
Q4 25
1.9%
Q3 25
0.2%
Q2 25
1.4%
Q1 25
3.7%
Q4 24
4.1%
Q3 24
2.0%
Q2 24
4.1%
Q1 24
10.0%
Cash Conversion
CHCI
CHCI
PACB
PACB
Q4 25
0.36×
Q3 25
-5.96×
Q2 25
1.51×
Q1 25
0.37×
Q4 24
1.03×
-12.93×
Q3 24
1.63×
Q2 24
1.35×
Q1 24
-2.46×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHCI
CHCI

Related Party$22.1M92%
Nonrelated Party$1.9M8%

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons